RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer
Udit Nindra(Camden and Campbelltown Hospitals), Wei Chua(Liverpool Hospital), Martin Hong(Calvary Mater Newcastle Hospital), Weng Ng(Sir Run Run Shaw Hospital), Stephanie Lim(Camden and Campbelltown Hospitals), Tara L. Roberts(Camden and Campbelltown Hospitals), Therese M. Becker(Liverpool Hospital), Adnan Nagrial(Westmead Hospital), Ray Asghari(Bankstown Lidcombe Hospital), Mark Wong, Jun Hee Hong(Liverpool Hospital), Lorraine Chantrill(Wollongong Hospital), Mahtab Farzin(Liverpool Hospital), Daniel Brungs(Wollongong Hospital), Tristan Rutland(Liverpool Hospital)
Cited by 0
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507